CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 80 filers reported holding CONCERT PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $156,331 | +40.8% | 26,769 | +20.4% | 0.00% | – |
| Q1 2021 | $111,000 | -87.5% | 22,225 | -68.3% | 0.00% | -100.0% |
| Q4 2020 | $885,000 | +25.0% | 70,014 | -2.9% | 0.00% | +33.3% |
| Q3 2020 | $708,000 | -2.3% | 72,114 | -1.1% | 0.00% | -25.0% |
| Q2 2020 | $725,000 | -2.9% | 72,914 | -13.7% | 0.00% | -20.0% |
| Q1 2020 | $747,000 | -7.5% | 84,501 | -3.6% | 0.01% | +66.7% |
| Q4 2019 | $808,000 | +56.0% | 87,614 | -0.6% | 0.00% | +50.0% |
| Q3 2019 | $518,000 | -73.2% | 88,114 | -45.3% | 0.00% | -71.4% |
| Q2 2019 | $1,934,000 | -2.8% | 161,134 | -2.2% | 0.01% | -12.5% |
| Q1 2019 | $1,990,000 | -4.8% | 164,834 | -1.0% | 0.01% | -11.1% |
| Q4 2018 | $2,090,000 | -53.8% | 166,525 | -45.4% | 0.01% | -47.1% |
| Q3 2018 | $4,523,000 | -17.7% | 304,755 | -6.7% | 0.02% | -26.1% |
| Q2 2018 | $5,496,000 | -30.6% | 326,555 | -5.5% | 0.02% | -36.1% |
| Q1 2018 | $7,915,000 | – | 345,625 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 968,198 | $9,634,000 | 3.29% |
| INGALLS & SNYDER LLC | 1,382,048 | $13,751,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 700,710 | $6,972,000 | 0.66% |
| Alambic Investment Management, L.P. | 17,900 | $178,000 | 0.45% |
| RA Capital Management | 1,858,474 | $18,492,000 | 0.36% |
| Perceptive Advisors | 2,150,641 | $21,398,000 | 0.35% |
| Eversept Partners, LP | 232,983 | $2,318,181 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 17,351 | $173,000 | 0.10% |
| Alyeska Investment Group, L.P. | 502,783 | $5,003,000 | 0.08% |
| KENNEDY CAPITAL MANAGEMENT LLC | 263,958 | $2,626,000 | 0.08% |